EFNB3 and cancer: Despite this general qualitative increase in expression, there are quantitative differences: ephrin-B1, B2, and A5 are far more highly expressed in invasive and metastatic samples than in DCIS, and the frequency of ephrin-B3 expression in all cancers seems to be lower than the other ligands.